Compare ProShares Ultra Silver ETF (AGQ) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Becton Dickinson and Co — how do they compare? ProShares Ultra Silver ETF trades at $65.7, while Becton Dickinson and Co trades at $151.68 (market cap $43.07B). The key difference: Becton Dickinson and Co pays a 2.69% dividend while ProShares Ultra Silver ETF pays none, and Becton Dickinson and Co is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | BDX | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $185.39 |
52-Week Low | $48.15 | $135.49 |
Market Cap | — | $43.07B |
Enterprise Value | — | $59.53B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) trades at $74.68, up 3.84% in the last session, though technical indicators show a bearish trend with moving averages and ADX signaling selling pressure. Recent news highlights significant volatility, including a 16% intraday crash on June 7, 2026, and concerns over beta slippage eroding silver's gains. The leveraged ETF structure amplifies both gains and losses, with silver prices facing headwinds from Federal Reserve rate expectations and import restrictions.
Outlook remains cautious due to AGQ's leveraged nature and silver market volatility. Investment opportunities exist if silver rallies, but risks include Fed policy impacts, technical bearish signals, and potential delivery squeezes. Analyst sentiment is mixed, with recent downgrades highlighting downside potential over the next 3-6 months.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
